Organisation paid for research Program year 2025 Source: CMS Open Payments

Florida Research Institute

Neither a doctor nor a teaching hospital

Research payments

$224,437

62 payments

Through program year 2025, Florida Research Institute is reported as receiving $224,437 in research payments, across 62 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $38,262 43
2024 Research $3,422 2
2022 Research $391 2
2021 Research $250 1
2020 Research $28,190 9
2019 Research $153,923 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $180,043 10 payments
  2. Boehringer Ingelheim International GmbH $41,100 42 payments
  3. E.R. Squibb & Sons, L.L.C. $1,777 6 payments
  4. Boehringer Ingelheim Finland Ky $673 1 payment
  5. Merck Sharp & Dohme Corporation $500 1 payment
  6. GlaxoSmithKline, LLC. $344 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double Blind Placebo Controlled 2 Part Adaptive Design Multicenter 12 Week Study to Assess Safety Tolerability and Efficacy of Ljn452 in Patients With Non Alcoholic Steatohepetatis Nash $83,682 3 payments
  2. A Randomized Double Blind Multicenter Study to Assess the Safety Tolerability and Efficacy of A Combination Treatment of Tropifexor Ljn452 and Cenicriviroc CVC in Adult Patients With Nonalcoholic Steatohepatitis Nash and Liver Fibrosis $78,491 1 payment
  3. Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis $37,918 41 payments
  4. Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study to Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response to Or Intolerance of Standard Therapy Amber $17,870 6 payments
  5. Phase IIa (PoCP) trial in UC $3,182 1 payment
  6. Phase IIB Study - F3 24 wk $987 3 payments
  7. Anti-Sema3A for DMI in Treated PDR patients $673 1 payment
  8. Phase IIB Study - F4 48 wk $631 2 payments
  9. A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis $500 1 payment
  10. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $344 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record